期刊
JOURNAL OF CLINICAL MEDICINE
卷 10, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/jcm10010152
关键词
denosumab; discontinuation; fracture; rebound; osteoporosis; turnover
Denosumab is a potent antiresorptive agent that can increase bone density and reduce fracture rates, but its effects reverse quickly upon discontinuation, leading to bone loss and increased bone turnover. Subsequent antiresorptive treatment is necessary to prevent fractures.
Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered. However, its favorable skeletal effects reverse quickly upon its discontinuation, because of a vast increase of osteoclast number and activity, which leads to a subsequent profound increase of bone turnover above pre-treatment values, a phenomenon commonly described as rebound phenomenon. More importantly, most patients experience rapid, profound bone loss due to this burst of bone resorption that may lead in a minority of these patients to occurrence of fractures, especially multiple vertebral fractures. Therefore, subsequent antiresorptive treatment is mandatory, although the optimal regimen is yet to be clarified. In the present review, we outline what is currently known regarding the negative effects of denosumab discontinuation on different aspects of bone status, the factors that may affect them, and strategies to prevent them.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据